PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29805580-9 2018 The reduction by PD98059 administration was comparable to that observed following fisetin treatment for 48 h. In conclusion, the current study demonstrates that fisetin inhibits the proliferation of gastric cancer cells and induces apoptosis through suppression of ERK 1/2 activation. fisetin 161-168 mitogen-activated protein kinase 3 Homo sapiens 265-272 29758489-6 2018 Fisetin decreased the translocation of nuclear transcription factor kappa-B (NF-kappaB) subunit p65 into the nucleus and inhibited the phosphorylation of proteins in the ERK1/2 pathway. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 170-176 33473265-5 2021 Further, fisetin also suppresses the activation of the PKCalpha/ROS/ERK1/2 and p38 MAPK signaling pathways, reduces the NF-kappaB activation, and down-regulates the level of the oncoprotein securin. fisetin 9-16 mitogen-activated protein kinase 3 Homo sapiens 68-74 31540162-6 2019 Fisetin treatment of TNF-alpha stimulated NHEKs also significantly inhibited the activation of p38 and JNK, but had enhanced effect on ERK1/2 (MAPK). fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 135-141 29758489-0 2018 Fisetin inhibits the generation of inflammatory mediators in interleukin-1beta-induced human lung epithelial cells by suppressing the NF-kappaB and ERK1/2 pathways. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 148-154 29805580-0 2018 Fisetin inhibits the proliferation of gastric cancer cells and induces apoptosis through suppression of ERK 1/2 activation. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 104-111 29805580-6 2018 Treatment of SGC7901 cells with fisetin for 48 h resulted in a reduction in the activation of ERK 1/2 in a concentration-dependent manner. fisetin 32-39 mitogen-activated protein kinase 3 Homo sapiens 94-101 29805580-7 2018 The reduction in activation of ERK 1/2 was significant following treatment with 15 microM fisetin for 48 h. The inhibitory effect of fisetin on activation of ERK 1/2 was further demonstrated using the ERK 1/2 inhibitor, PD98059. fisetin 90-97 mitogen-activated protein kinase 3 Homo sapiens 31-38 29805580-7 2018 The reduction in activation of ERK 1/2 was significant following treatment with 15 microM fisetin for 48 h. The inhibitory effect of fisetin on activation of ERK 1/2 was further demonstrated using the ERK 1/2 inhibitor, PD98059. fisetin 90-97 mitogen-activated protein kinase 3 Homo sapiens 158-165 29805580-7 2018 The reduction in activation of ERK 1/2 was significant following treatment with 15 microM fisetin for 48 h. The inhibitory effect of fisetin on activation of ERK 1/2 was further demonstrated using the ERK 1/2 inhibitor, PD98059. fisetin 90-97 mitogen-activated protein kinase 3 Homo sapiens 158-165 29805580-7 2018 The reduction in activation of ERK 1/2 was significant following treatment with 15 microM fisetin for 48 h. The inhibitory effect of fisetin on activation of ERK 1/2 was further demonstrated using the ERK 1/2 inhibitor, PD98059. fisetin 133-140 mitogen-activated protein kinase 3 Homo sapiens 31-38 29805580-7 2018 The reduction in activation of ERK 1/2 was significant following treatment with 15 microM fisetin for 48 h. The inhibitory effect of fisetin on activation of ERK 1/2 was further demonstrated using the ERK 1/2 inhibitor, PD98059. fisetin 133-140 mitogen-activated protein kinase 3 Homo sapiens 158-165 29805580-7 2018 The reduction in activation of ERK 1/2 was significant following treatment with 15 microM fisetin for 48 h. The inhibitory effect of fisetin on activation of ERK 1/2 was further demonstrated using the ERK 1/2 inhibitor, PD98059. fisetin 133-140 mitogen-activated protein kinase 3 Homo sapiens 158-165 28204814-6 2017 Fisetin also decreased the phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk)1/2, but had no effect on the phosphorylation of p38 mitogen-activated protein kinase (MAPK). fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 61-107 29467859-0 2018 Fisetin inhibits the growth and migration in the A549 human lung cancer cell line via the ERK1/2 pathway. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 90-96 27551764-0 2016 Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-kappaB/mTOR and ERK1/2 signaling pathways. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 82-88 27793939-0 2016 Fisetin Reduces Cell Viability Through Up-Regulation of Phosphorylation of ERK1/2 in Cholangiocarcinoma Cells. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 75-81 27551764-6 2016 Additionally, fisetin suppressed TU212 cells proliferation, which was linked with ERK1/2 inactivation. fisetin 14-21 mitogen-activated protein kinase 3 Homo sapiens 82-88 26101063-5 2015 Fisetin significantly attenuated TPA-induced cell invasion in MCF-7 human breast cancer cells, and was found to inhibit the activation of the PKCalpha/ROS/ERK1/2 and p38 MAPK signaling pathways. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 155-161 24466036-8 2014 BRAF mutated melanoma cells were more sensitive to fisetin treatment, and this was associated with a decrease in the phosphorylation of MEK1/2 and ERK1/2. fisetin 51-58 mitogen-activated protein kinase 3 Homo sapiens 147-153 23940799-7 2013 Fisetin suppressed the TPA (tetradecanoylphorbol-13-acetate)-induced activation of p38 MAPK and uPA, and inhibited the TPA-enhanced migratory and invasive abilities. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 87-91 23940799-9 2013 This study provides strong evidence for the molecular mechanism of fisetin in inhibiting the aggressive phenotypes by repression of uPA via interruption of p38 MAPK-dependent NF-kappaB signaling pathway in cervical cancer cells and thus contributes insight to the potential of using fisetin as a therapeutic strategy against cervical cancer by inhibiting migration and invasion. fisetin 67-74 mitogen-activated protein kinase 3 Homo sapiens 160-164 19725538-2 2009 Fisetin exhibited an inhibitory effect on the abilities of adhesion, migration, and invasion via inhibiting the phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and downregulating the expressions of matrix metalloproteinase-2 (MMP-2) and urokinase-type plasminogen activator (u-PA) at both the protein and mRNA levels in A549 cells. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 178-184 19725538-5 2009 Furthermore, reduction of ERK1/2 phosphorylation by ERK small interfering RNA (ERK siRNA) potentiated the effect of fisetin, supporting the inhibition of ERK1/2 being beneficial to antimetastasis. fisetin 116-123 mitogen-activated protein kinase 3 Homo sapiens 26-32 19725538-5 2009 Furthermore, reduction of ERK1/2 phosphorylation by ERK small interfering RNA (ERK siRNA) potentiated the effect of fisetin, supporting the inhibition of ERK1/2 being beneficial to antimetastasis. fisetin 116-123 mitogen-activated protein kinase 3 Homo sapiens 154-160 25527158-0 2015 Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1/2. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 118-124 25527158-6 2015 Our results showed that fisetin phosphorylated ERK1/2 in a sustained way that contributed to the inhibited ADAM9 protein and mRNA expression determined by Western blot and RT-PCR. fisetin 24-31 mitogen-activated protein kinase 3 Homo sapiens 47-53 23940799-0 2013 Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-kappaB signaling pathway. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 161-165 21964635-0 2012 Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8-/caspase-3-dependent pathway. fisetin 0-7 mitogen-activated protein kinase 3 Homo sapiens 70-76 21964635-5 2012 Moreover, treatment of HeLa cells with fisetin induced a sustained activation of the phosphorylation of ERK1/2, and inhibition of ERK1/2 by PD98059 (MEK1/2 inhibitor) or transfection with the mutant ERK1/2 expression vector significantly abolished the fisetin-induced apoptosis through the activation of caspase-8/-3 pathway. fisetin 39-46 mitogen-activated protein kinase 3 Homo sapiens 104-110 21964635-5 2012 Moreover, treatment of HeLa cells with fisetin induced a sustained activation of the phosphorylation of ERK1/2, and inhibition of ERK1/2 by PD98059 (MEK1/2 inhibitor) or transfection with the mutant ERK1/2 expression vector significantly abolished the fisetin-induced apoptosis through the activation of caspase-8/-3 pathway. fisetin 39-46 mitogen-activated protein kinase 3 Homo sapiens 130-136 21964635-5 2012 Moreover, treatment of HeLa cells with fisetin induced a sustained activation of the phosphorylation of ERK1/2, and inhibition of ERK1/2 by PD98059 (MEK1/2 inhibitor) or transfection with the mutant ERK1/2 expression vector significantly abolished the fisetin-induced apoptosis through the activation of caspase-8/-3 pathway. fisetin 39-46 mitogen-activated protein kinase 3 Homo sapiens 130-136